Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $23 from $20 and keeps an Outperform rating on the shares. The company’s positive topline Phase 2b announcement builds a strong case for Haduvio to broadly address idiopathic pulmonary fibrosis chronic cough, in which no options are approved and candidates elsewhere have disappointed, the analyst tells investors in a research note. The firm says the placebo-like discontinuation rate across the active arms should resolve a key investor concern. Today’s selloff “reflects small-cap biotech trading dynamics that have become all too familiar in the current market environment,” contends Oppenheimer.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics announces $100M common stock offering
- Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
- Trevi Therapeutics Reports Positive Phase 2b Trial Results
- Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
- Trevi Therapeutics’ Strong Market Potential and Revenue Opportunities Highlighted in Buy Rating